Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.11 USD
-0.40 (-8.78%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $4.11 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Income Statements
Fiscal Year end for Aquestive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 51 | 48 | 51 | 46 | 53 |
Cost Of Goods | 21 | 19 | 15 | 13 | 20 |
Gross Profit | 30 | 28 | 36 | 33 | 32 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 70 | 71 | 76 | 85 |
Income After Depreciation & Amortization | -15 | -42 | -35 | -43 | -53 |
Non-Operating Income | 15 | 0 | -13 | 0 | -4 |
Interest Expense | 7 | 12 | 22 | 13 | 9 |
Pretax Income | -8 | -54 | -71 | -56 | -66 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -54 | -71 | -56 | -66 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -54 | -71 | -56 | -66 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -12 | -39 | -28 | -37 | -48 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 7 | 6 | 5 |
Income After Depreciation & Amortization | -15 | -42 | -35 | -43 | -53 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 61.26 | 48.73 | 38.08 | 33.65 | 25.36 |
Diluted EPS Before Non-Recurring Items | -0.13 | -1.12 | -1.49 | -1.66 | -2.42 |
Diluted Net EPS (GAAP) | -0.13 | -1.12 | -1.85 | -1.66 | -2.61 |
Fiscal Year end for Aquestive Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13.21 | 13.00 | 13.24 | 11.13 |
Cost Of Goods | NA | 4.68 | 4.80 | 6.62 | 4.74 |
Gross Profit | NA | 8.53 | 8.20 | 6.62 | 6.40 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 12.44 | 10.59 | 10.83 | 11.01 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.91 | -2.39 | -4.21 | -4.61 |
Non-Operating Income | NA | -0.86 | 1.51 | 0.13 | 14.16 |
Interest Expense | NA | 3.24 | 1.31 | 1.43 | 1.49 |
Pretax Income | NA | -8.01 | -2.18 | -5.51 | 8.07 |
Income Taxes | NA | 0.10 | -0.14 | 0.28 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.11 | -2.04 | -5.79 | 8.07 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.11 | -2.04 | -5.79 | 8.07 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 67.20 | 64.68 | 57.35 | 73.79 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.03 | -0.10 | 0.11 |
Diluted Net EPS (GAAP) | NA | -0.11 | -0.03 | -0.10 | 0.11 |